



WEDNESDAY 21st SEPTEMBER 2016 COMMENCING 9.30 AM

AT [THE ANGEL HOTEL](#), ABERGAVENNY, NP7 5EN

AGENDA

Enclosure

1. **Welcome and introduction**

2. **Apologies**

3. **Declarations of interest**

4. **Minutes of previous meeting**

1/AWMSG/0916

To protect commercial confidentiality the following appraisal will be held in private

5. **Appraisal 1: Full Submission WPAS Golimumab (Simponi[®])** for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein and/or magnetic resonance imaging evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs

2/AWMSG/0916
Appendices

The meeting will open to the public at approximately 10.30 am

6. **Chairman's report (verbal update)**

7. **Appraisal 2: Full Submission Green tea leaf extract (Catephen[®])** for the cutaneous treatment of external genital and perianal warts (condylomata acuminata) in immunocompetent patients from the age of 18 years

3/AWMSG/0916
Appendices

8. **Appraisal 3: Full Submission Brivaracetam (Briviact[®])** adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy

4/AWMSG/0916
Appendices

9. **Feedback from AWPAG Meeting 22nd June 2016**

5/AWMSG/0916

10. **Prescribing of Low Molecular Weight Heparin in Wales**

6/AWMSG/0916

- | | | |
|-----|---|-----------------------------|
| 11. | Prescribing of Amiodarone for Atrial Fibrillation and Atrial Flutter in Wales | 7/AWMSG/0916 |
| 12. | Safeguarding Users of Opioid Patches by Standardising Patient/Caregiver Counselling | 8/AWMSG/0916 |
| 13. | Appraisal 4: Limited Submission
Rilpivirine (Edurant®) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive patients from 12 years old to < 18 years old with a viral load ≤ 100,000 HIV-1 RNA copies/ml | 9/AWMSG/0916
Appendices |
| 14. | Appraisal 5: Limited Submissions
Emtricitabine/tenofovir alafenamide (Descovy®) in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV-1) | 10/AWMSG/0916
Appendices |
| 15. | Guidance for partnership working between NHS organisations, primary care contractors, the pharmaceutical industry and the allied commercial sector in Wales – document update | 11/AWMSG/0916 |
| 16. | All Wales NOAC Alert Card | 12/AWMSG/0916 |
| 17. | Therapeutic Priorities and Clinical Effectiveness Prescribing Programme Summary 2016–2017 | 13/AWMSG/0916 |
| 18. | NPI 2015-2016 Annual Primary Care Prescribing Report | 14/AWMSG/0916 |

Date of next meeting: 12th October 2016 in Cardiff